 ATLANTA, Feb. 22, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics for Parkinsons disease and related disorders, today announced that it will present findings from its oral therapy studies for... 